AstraZeneca
AZN
1,249 hedge funds and large institutions have $37.6B invested in AstraZeneca in 2025 Q1 according to their latest regulatory filings, with 151 funds opening new positions, 521 increasing their positions, 375 reducing their positions, and 94 closing their positions.
191% more call options, than puts
Call options by funds: $855M | Put options by funds: $294M
69% more funds holding in top 10
Funds holding in top 10: 13 → 22 (+9)
61% more first-time investments, than exits
New positions opened: 151 | Existing positions closed: 94
39% more repeat investments, than reductions
Existing positions increased: 521 | Existing positions reduced: 375
10% more capital invested
Capital invested by funds: $34.2B → $37.6B (+$3.47B)
3% more funds holding
Funds holding: 1,218 → 1,249 (+31)
0.28% less ownership
Funds ownership: 16.58% → 16.3% (-0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
+$666M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$565M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$179M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$117M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$117M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$450M |
| 2 |
Jennison Associates
New York
|
-$352M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$236M |
| 4 |
D.E. Shaw & Co
New York
|
-$226M |
| 5 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$211M |
AZN Hedge Fund Activity: Q1 2025 in Review
1,249 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2025, worth a combined $37.6B — up 10% from $34.2B a quarter earlier.
Buyers outnumbered sellers: 151 funds opened new AZN positions and 94 closed out — a net gain of 57 holders — while 521 added to existing stakes and 375 trimmed.
The largest buyer was Fisher Asset Management, adding an estimated $666M. The largest seller was Capital International Investors, cutting an estimated $450M.
- 1,249 institutional investors held AstraZeneca (AZN) as of Q1 2025, up from 1,218 in Q4 2024.
- Funds reported $37.6B of AstraZeneca stock for Q1 2025, up 10% quarter-over-quarter.
- 151 funds opened new AstraZeneca positions in Q1 2025 and 94 closed out, a net change of +57 holders.
- The largest AstraZeneca buyer in Q1 2025 was Fisher Asset Management, an estimated $666M added.
- The largest AstraZeneca seller in Q1 2025 was Capital International Investors, an estimated $450M sold.
Based on aggregated 13F filings for Q1 2025.